Literature DB >> 31930215

Tuberculosis drug resistance in Canada: 2018.

Marie LaFreniere1, Demy Dam1,2,3, Lori Strudwick4, Sarah McDermott1.   

Abstract

BACKGROUND: Drug-resistant tuberculosis (TB) is a public health issue of global importance that poses a threat to TB control efforts. Canada conducts nationwide surveillance to monitor emerging drug resistance trends and document progress towards reaching the goal of TB elimination.
OBJECTIVE: To describe TB drug resistance trends across Canada from 2008-2018, with a focus on 2018, by drug resistance, geographic and demographic patterns.
METHODS: TB drug resistance data are captured through two independent surveillance systems managed by the Public Health Agency of Canada: Canadian Tuberculosis Laboratory Surveillance System (CTBLSS) and the Canadian Tuberculosis Reporting System (CTBRS). Data from these systems were analyzed and descriptive statistics were reported by resistance profile, place of residence (province), age groups, sex and country of birth.
RESULTS: In 2018, 1,459 TB isolates underwent drug susceptibility testing, a 4.3% decrease from 2017. Resistance to any first-line drug was reported in 148 isolates (10.1%), compared to 123 (8.1%) in 2017. Of these, 121 were monoresistant, five were polyresistant, 21 were multidrug-resistant tuberculosis (MDR-TB) and one was extensively drug-resistant TB (XDR-TB). Drug resistance was reported in all provinces and territories except Prince Edward Island, Northwest Territories and Yukon. Among individuals younger than 15 years, very little TB drug resistance was detected. Among individuals aged 15 years and older, the distribution of TB drug resistance varied with no discernable trends. The proportion of drug resistance was slightly higher in females than in males. By origin, 10.7% of foreign-born TB cases reported between 2006 and 2016 were drug-resistant. Among the Canadian-born non-Indigenous cases, 9.3% were drug resistant; among Canadian-born Indigenous, 2.4% were drug resistant.
CONCLUSION: In 2018, the proportion of isolates with TB drug resistance in Canada remained low and below global averages, with stable drug resistance, both geographically and demographically.

Entities:  

Keywords:  Canada; drug resistance; surveillance; tuberculosis

Year:  2020        PMID: 31930215      PMCID: PMC6941922          DOI: 10.14745/ccdr.v46i01a02

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN: 1188-4169


  2 in total

1.  Tuberculosis drug resistance in Canada: 2017.

Authors:  M LaFreniere; H Hussain; J Vachon
Journal:  Can Commun Dis Rep       Date:  2018-11-01

2.  Tuberculosis in Canada: 2017.

Authors:  M LaFreniere; H Hussain; N He; M McGuire
Journal:  Can Commun Dis Rep       Date:  2019-02-07
  2 in total
  4 in total

Review 1.  Dimensions of poverty as risk factors for antimicrobial resistant organisms in Canada: a structured narrative review.

Authors:  Teagan King; Richelle Schindler; Swati Chavda; John Conly
Journal:  Antimicrob Resist Infect Control       Date:  2022-01-24       Impact factor: 4.887

2.  Rifampin-resistant/multidrug-resistant Tuberculosis in Alberta, Canada: Epidemiology and treatment outcomes in a low-incidence setting.

Authors:  Brett D Edwards; Jenny Edwards; Ryan Cooper; Dennis Kunimoto; Ranjani Somayaji; Dina Fisher
Journal:  PLoS One       Date:  2021-02-16       Impact factor: 3.240

3.  Analysis of drug resistance and mutation profiles in Mycobacterium tuberculosis isolates in a surveillance site in Beijing, China.

Authors:  Jie Zhang; Yixuan Ren; Liping Pan; Junli Yi; Tong Guan; Xinyu Yang; Zongde Zhang
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

4.  Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan.

Authors:  Fuminori Mizukoshi; Nobuyuki Kobayashi; Fumiko Kirikae; Ken Ohta; Kazunari Tsuyuguchi; Noritaka Yamada; Yoshikazu Inoue; Masahide Horiba; Noriko Kawata; Akiko Ichinose; Tohru Miyoshi-Akiyama; Reiko Kiritani; Keiji Funatogawa; Teruo Kirikae
Journal:  mSphere       Date:  2021-07-07       Impact factor: 4.389

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.